Regeneron Pharmaceuticals (REGN) EBIT Margin (2009 - 2026)

Regeneron Pharmaceuticals' EBIT Margin history runs 18 years deep, the most recent figure standing at 17.83% for Q1 2026.

• In Q1 2026, EBIT Margin fell 170.0% year-over-year to 17.83%; the TTM figure through Mar 2026 stood at 24.32% (down 287.0% YoY), while the FY2025 annual figure was 24.95%, down 315.0% from the prior year.
• EBIT Margin was 17.83% for Q1 2026 at Regeneron Pharmaceuticals, down from 22.65% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 2517.0% in Q1 2022 to a low of 17.83% in Q1 2026.
• Historically, EBIT Margin has averaged 240.97% across 5 years, with a median of 29.94% in 2023.
• The sharpest annual moves came in 2022 and 2023: EBIT Margin jumped 247300 bps in 2022, then sank 248706 bps in 2023.
• A 5-year view of EBIT Margin shows it stood at 1146.8% in 2022, then plunged by 98 bps to 28.33% in 2023, then slipped by 8 bps to 26.13% in 2024, then decreased by 13 bps to 22.65% in 2025, then decreased by 21 bps to 17.83% in 2026.
• The last three EBIT Margin figures came in at 17.83% (Q1 2026), 22.65% (Q4 2025), and 27.35% (Q3 2025), per Business Quant data.